0001209191-16-140417.txt : 20160907
0001209191-16-140417.hdr.sgml : 20160907
20160907164712
ACCESSION NUMBER: 0001209191-16-140417
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160907
FILED AS OF DATE: 20160907
DATE AS OF CHANGE: 20160907
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SEQUENOM INC
CENTRAL INDEX KEY: 0001076481
STANDARD INDUSTRIAL CLASSIFICATION: MEASURING & CONTROLLING DEVICES, NEC [3829]
IRS NUMBER: 770365889
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3595 JOHN HOPKINS COURT
CITY: SAN DIEGO
STATE: X1
ZIP: 92121
BUSINESS PHONE: 8582029000
MAIL ADDRESS:
STREET 1: 3595 JOHN HOPKINS COURT
CITY: SAN DIEGO
STATE: X1
ZIP: 92121
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SLACIK CHARLES P
CENTRAL INDEX KEY: 0001204660
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-29101
FILM NUMBER: 161873875
MAIL ADDRESS:
STREET 1: 250 S. KRAEMER BLVD
CITY: BREA
STATE: CA
ZIP: 92821
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2016-09-07
1
0001076481
SEQUENOM INC
SQNM
0001204660
SLACIK CHARLES P
3595 JOHN HOPKINS COURT
SAN DIEGO
CA
92121
1
0
0
0
Common Stock
2016-09-07
4
U
0
56397
D
0
D
Non-Qualified Stock Option (right to buy)
1.11
2016-09-07
4
D
0
20000
D
2026-06-14
Common Stock
20000
0
D
Non-Qualified Stock Option (right to buy)
2.33
2016-09-07
4
D
0
24864
D
2024-01-01
Common Stock
24864
0
D
Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated July 26, 2016, among the Issuer, Laboratory Corporation of America Holdings, a Delaware corporation ("Parent"), and Savoy Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $2.40 per share, without interest, subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger").
This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
/s/ Jeffrey D. Linton, as attorney-in-fact For: Charles Slacik
2016-09-07